The challenge: Antimicrobial resistance in livestock is a public health threat due to the risk of zoonotic transmission to humans and its negative consequences on animal health and welfare when diseases cannot be treated. Antimicrobial treatment options for pigs are increasingly limited because of planned restrictions in the use of colistin and zinc, two current choices for treatment of post-weaning diarrhoea.
The solution: AVANT is a multi-actor inter-sectorial project aimed at developing alternatives to antimicrobials for the management of bacterial infections in pigs, especially diarrhoea during the weaning period, as the major indication for antimicrobial use in livestock in Europe. During pre-clinical studies, efficacy, toxicity, and mode of action of these interventions is tested, and their dosage and formulation optimized. The results and a survey for veterinarian-, farmer- and consumers perception of antimicrobial alternatives, will be used together with legal and economic considerations to select three interventions for large-scale farm trials, assessing clinical efficacy and impact on antimicrobial use.
The main impacts: The AVANT portfolio comprises a variety of alternatives for treatment or prevention of diarrhoea and/or respiratory infections, namely:
- Gut-stabilizing interventions based on a symbiotic (pre- and probiotic) product and faecal microbiota transplantation
- Novel veterinary medicinal products containing bacteriophages and polymers for targeted treatment of enterotoxigenic coli infections
- Immuno-stimulating injectable and feed additive products
- Alternative feeding strategies targeting sows and piglets
All steps are supported by regulatory advice for quick market entry post-project. Generated and existing data on antimicrobial use, pig demographics and projected consumption of pork, will be used in mathematical modelling to estimate the reduction in antimicrobial use that could be achieved by 2030, if the AVANT alternatives were widely adopted in pig production.
The funding: AVANT has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 862829.
- EC Contribution: €5.99 million
- Start date: 01/01/2020
- Duration: 48 months